Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33 heavily pretreated patients with metastatic melanoma…
BEIJING--(BUSINESS WIRE)--Beijing Avistone Biotechnology Co., Ltd (āAvistoneā), an innovative biotechnology company focused on precision oncology therapeutics, today announced…
Sign in to your account